BriaCell Therapeutics Corp. (BCTX)

SEC fundamentals · as filed in 10-K FY2026, period ended Jul 31, 2026 · updated Oct 30, 2026

Other listed symbols of this issuer: BCTXL, BCTXZ

Verified against EDGAR
Total Assets
$23.6M
Stockholders' Equity
$15.6M
Cash & Equivalents
$9.9M
Long-Term Debt
—

as filed in 10-K FY2026, period ended Jul 31, 2026 · View filings on EDGAR ↗

In its 10-K for the period ended Jul 31, 2026, BriaCell Therapeutics Corp. reported net income of -$34.9M and total assets of $23.6M. Every figure below is taken directly from BriaCell Therapeutics Corp.'s SEC filings: each links to the source document on EDGAR.

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2026—-$34.9M
FY2025—-$26.3M
FY2024—-$4.8M
FY2023—-$20.3M
FY2022—-$26.8M
FY2021—-$13.8M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
10-KOct 28, 2026on EDGAR ↗
8-KJun 26, 2026on EDGAR ↗
10-QJun 9, 2026on EDGAR ↗
8-KJun 3, 2026on EDGAR ↗
8-KMar 31, 2026on EDGAR ↗
10-QMar 10, 2026on EDGAR ↗
8-KMar 9, 2026on EDGAR ↗
8-KFeb 20, 2026on EDGAR ↗
DEF 14AFeb 12, 2026on EDGAR ↗
8-KJan 15, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jul 31, 2026 · 10-K

Total Assets$23.6Msource ↗
Stockholders’ Equity$15.6Msource ↗
Cash & Equivalents$9.9Msource ↗
Long-Term Debt—source ↗

Income Statement

10-K (annual) · period ended Jul 31, 2026

Revenue—source ↗
Net Income-$34.9Msource ↗
Operating Income-$36.1Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$29.2Msource ↗

Per Share & Cash Flow

10-K (annual) · period ended Jul 31, 2026

EPS (diluted)$-6.97source ↗
EPS (basic)$-6.97source ↗
Shares Outstanding8.7Msource ↗
Cash from Operations-$28.7Msource ↗
Cash from Financing$31.8Msource ↗
Cash from Investing-$3.8Msource ↗

Restatement history

Point-in-time

No material restatements detected across 111 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.

Deeper fundamentals

A free API key reaches BCTX’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Get a free API key →See plans

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/BCTX

MCP tool: get_sec_fundamentals ticker=BCTX

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/BCTX/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=BCTX as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/BCTX/history

MCP tool: get_fundamentals_history ticker=BCTX

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/financial-health/BCTX

MCP tool: get_financial_health ticker=BCTX

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.